Phase 1-2a dose-ranging study of TLK286 [canfosfamide] in combination with Doxil [doxorubicin liposomal] in platinum refractory or resistant ovarian cancer.
Phase of Trial: Phase I/II
Latest Information Update: 22 Jul 2011
At a glance
- Drugs Canfosfamide; Doxorubicin liposomal
- Indications Ovarian cancer
- Focus Adverse reactions; Therapeutic Use
- 22 Jul 2011 Actual end date (Mar 2006) added as reported by ClinicalTrials.gov.
- 12 Jun 2007 Status changed from in progress to completed.
- 28 Sep 2005 New trial record.